Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation


Phase 2 Results

Summary of Purpose

The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled, dose-adjusted Vitamin-K antagonists (VKA) (aiming for an international normalized ratio (INR) 2.0 to 3.0) in patients with non-valvular atrial fibrillation (AF) with one or more additional...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 20 March 2012.

1 Feb 2007 22 May 2008 1 Jun 2008 1 Jun 2008 1 Mar 2012 17 Aug 2011
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Purpose: Prevention
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment


Not available